Leadership
Our team of passionate biopharmaceutical leaders combines deep expertise in drug development and commercialization
Meet our leadership teamLatest news
View more news >Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Rare perspective
Insights and information on our approach to collaborating with rare disease communities, supporting our teammates at Ultragenyx, and developing new therapies for rare disease
Read our blog >